IC50 values for refametinib, copanlisib, lapatinib and the effect of trastuzumab on growth inhibition in a panel of HER2-positive breast cancer cell lines including parental cells (-P) and matched models of acquired trastuzumab (-T and -Res) and lapatinib (-L) resistance. The gene discussed is ERBB2; the disease is breast cancer.